CAJ | 학술논문

目的：探讨中药喜丹汤联合化疗治疗广泛期小细胞肺癌能否提高疗效。方法：经病理明确诊断的未经手术治疗的120例广泛期小细胞肺癌患者，随机分为对照组与研究组各60例，对照组采用EP方案化疗治疗，研究组采用中药喜丹汤联合EP方案治疗。结果：研究组与对照组总有效率(CR+PR)分别为75.0%(45/60)、56.7%(33/60)，两组比较有统计学差异(P<0.05)，中位生存时间及生存时间曲线：研究组10.9个月(10.5~11.2)；对照组8.1个月(7.4~8.8)，两组比较有显著的统计学意义(P<0.001)；1年生存率研究组为53.3%(32/60)，对照组为31.7%(19/60)，两组比较差异有统计学意义(P<0.05)；常见的毒副反应主要表现为血液学毒性及胃肠道反应，患者均可耐受。结论：中药联合化疗能提高广泛期小细胞肺癌的疗效，延长其生存期。
목적：탐토중약희단탕연합화료치료엄범기소세포폐암능부제고료효。방법：경병리명학진단적미경수술치료적120례엄범기소세포폐암환자，수궤분위대조조여연구조각60례，대조조채용EP방안화료치료，연구조채용중약희단탕연합EP방안치료。결과：연구조여대조조총유효솔(CR+PR)분별위75.0%(45/60)、56.7%(33/60)，량조비교유통계학차이(P<0.05)，중위생존시간급생존시간곡선：연구조10.9개월(10.5~11.2)；대조조8.1개월(7.4~8.8)，량조비교유현저적통계학의의(P<0.001)；1년생존솔연구조위53.3%(32/60)，대조조위31.7%(19/60)，량조비교차이유통계학의의(P<0.05)；상견적독부반응주요표현위혈액학독성급위장도반응，환자균가내수。결론：중약연합화료능제고엄범기소세포폐암적료효，연장기생존기。
Objective:To investigate the clinic effect of traditional Chinese medicine combined with chemotherapy in treating exten-sive stage small cell lung cancer( ES-SCLC) . Methods:120 cases of patients with ES-SCLC treated without surgery were divided ran-domly into the control group treated with EP regimen and the experimental group treated with traditional Chinese medicine ( XIDAN soup) combined with EP regimen,with sixty patients in each group. Results:In the study group the overall response rate( CR+PR) was 75. 0%,In the control group the overall response rate( CR+PR) was 56. 7%. There was statistical difference in the overall response rate between the two groups(P<0. 05). The median survivals and time-survivor curve for the control group and study group were 8. 1 months and 10. 9 months respectively,which was statistically different between the two groups(P<0. 05). 1 year survival rate for the control group and study group were 53. 3% and 31. 7%,respectively,which was statistically different between the two groups(P <0. 05). The major side effects were hematologic toxicities and gastrointestinal reactions,and the patients can tolerate it. Conclusion:The treatment of Chinese medicine combined with chemotherapy can improve the therapeutic efficacy and prolong survival period of ES-SCLC patients.